Oxford Ovarian Cancer Predict Chemotherapy Response 01

计划入组 35 人 · 首次发布于 2013 年 1 月 17 日

Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)

计划入组 2,000 人 · 首次发布于 2026 年 8 月 19 日

Oxford Pleural Embolisation Trial

计划入组 106 人 · 首次发布于 2024 年 10 月 22 日

Cancer vaccines (Oxford Vacmedix)

Meningitis B (University of Oxford)

MVA PvDBP

Banyan Biomarkers, Inc.

United States

Cognizance Biomarkers, LLC

United States

SUMMIT (OXFORD) LIMITED

United Kingdom

Oxford Cancer Biomarkers Partners with Mira Precision Health to Advance ToxNav® Test for 5FU/Capecitabine Toxicity Prediction in US Market

Oxford BioDynamics' EpiSwitch Biomarkers Show Promise in Pfizer Bladder Cancer Trial

Oxford and GSK Launch £50 Million Program to Develop Cancer Prevention Vaccine